BOZEMAN, Mont. (AP) — A Japanese pharmaceutical company has purchased Bozeman-based LigoCyte Pharmaceuticals in a $60 million deal.
The executive vice president of Takeda Pharmaceutical Co.'s vaccine business division, Rajeev Venkayya, says LigoCyte's work on a vaccine to prevent norovirus was identified as having potential for global impact.
LigoCyte CEO Donald P. Beeman tells the Bozeman Daily Chronicle (http://bit.ly/SHCwbD) that LigoCyte will remain in Bozeman for the foreseeable future and intends to retain its 37 employees.
Takeda, based in Osaka, Japan, had sales of about $19.2 billion in the last fiscal year and invests about $3.8 billion in research and development each year.
Information from: Bozeman Daily Chronicle, http://www.bozemandailychronicle.com
What's On TonightFull Schedule